Stem Cell, Precursor Cell, or Target Cell-Based Treatment of Multi-Organ Failure and Renal Dysfunction

Abstract

Methods for the treatment of acute renal failure, multi-organ failure, early dysfunction of kidney transplant, chronic renal failure, organ dysfunction, and wound healing are provided. The methods include delivering a therapeutic amount of hematopoietic stem cells, non-hematopoietic, mesenchymal stem cells, hemangioblasts, and pre-differentiated cells to a patient in need thereof.

1 . A method of treating multi-organ failure, kidney dysfunction, or wound healing, said method comprising delivering a therapeutic amount of stem cells to a patient in need thereof. 
     
     
         2 . (canceled) 
     
     
         3 . The method of  claim 1  wherein said stem cells comprise mesenchymal stem cells. 
     
     
         4 - 5 . (canceled) 
     
     
         6 . The method of  claim 1  wherein said stem cells comprise non-transformed stem cells. 
     
     
         7 . The method of  claim 1  wherein said stem cells comprise genetically modified stem cells, wherein protective potency of said cells is augmented by genetic modification prior to administration in a patient in need thereof. 
     
     
         8 . The method of  claim 1  wherein said stem cells comprise autologous cells. 
     
     
         9 . The method of  claim 1  wherein said stem cells comprise allogeneic cells. 
     
     
         10 . The method of  claim 1  wherein said kidney dysfunction comprises early dysfunction of kidney transplant or chronic renal failure. 
     
     
         11 - 17 . (canceled) 
     
     
         18 . A method of treating multi-organ failure, kidney dysfunction, wound healing or organ dysfunction comprising delivering a therapeutic amount of a stimulant of stem cell mobilization to a patient in need thereof;
 wherein the stimulant mobilizes stem cells to the organs in need thereof.   
     
     
         19 . The method of  claim 18  wherein said stimulant of stem cell mobilization is SDF-1. 
     
     
         20 . The method of  claim 18  wherein said stem cells comprise mesenchymal stem cells. 
     
     
         21 - 44 . (canceled) 
     
     
         45 . A method of treating multi-organ failure, kidney dysfunction, organ dysfunction, or wound healing, said method comprising delivering a therapeutic amount of a mixture hematopoietic stem cells and mesenchymal stem cells to a patient in need thereof. 
     
     
         46 . The method of  claim 45  wherein said kidney dysfunction comprises acute renal failure, early dysfunction of kidney transplant, or chronic renal failure. 
     
     
         47 . The method of  claim 45  wherein said hematopoietic stem cells and said mesenchymal stem cells comprise autologous cells. 
     
     
         48 . The method of  claim 45  wherein said hematopoietic stem cells and said mesenchymal stem cells comprise allogeneic cells. 
     
     
         49 . The method of  claim 45  wherein a ratio of said hematopoietic stem cells to said mesenchymal stem cells is optimized for the treatment of kidney dysfunction or other organ dysfunction. 
     
     
         50 . The method of  claim 49  wherein said stem cells are delivered to said patient in a ratio of about 0.1:1 to about 50:1 hematopoietic stem cells to mesenchymal stem cells. 
     
     
         51 - 59 . (canceled) 
     
     
         60 . The method of  claim 3 , wherein the mesenchymal stem cells are isolated from bone marrow aspirates and adhere to the bottom of a culture dish while substantially all other cell types remain in suspension. 
     
     
         61 . The method of  claim 45 , wherein the mesenchymal stem cells are isolated from bone marrow aspirates and adhere to the bottom of a culture dish while substantially all other cell types remain in suspension.